Need Assistance?
  • US & Canada:
    +
  • UK: +

PG-SPI

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

PG-SPI is an antimicrobial peptide found in Pseudophryne guentheri (Australian myobatrachid frog, Guenther's toadlet), and has antimicrobial activity.

Category
Functional Peptides
Catalog number
BAT-011663
Molecular Formula
C59H81N13O17S
Molecular Weight
1276.43
IUPAC Name
(S)-5-(((S)-1-(((S)-1-((2-(((S)-1-(((S)-1-amino-4-(methylthio)-1-oxobutan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-2-oxoethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-4-((S)-3-carboxy-2-((S)-1-(((S)-5-oxopyrrolidine-2-carbonyl)-L-prolyl-L-asparaginyl)pyrrolidine-2-carboxamido)propanamido)-5-oxopentanoic acid
Synonyms
pGlu-Pro-Asn-Pro-Asp-Glu-Phe-Phe-Gly-Leu-Met-NH2; Substance P-like peptide 1; Recombinant Pseudophryne guentheri Substance P-like peptide 1; H-Pyr-Pro-Asn-Pro-Asp-Glu-Phe-Phe-Gly-Leu-Met-NH2; L-pyroglutamyl-L-prolyl-L-asparagyl-L-prolyl-L-alpha-aspartyl-L-alpha-glutamyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-leucyl-L-methioninamide; (4S)-5-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2-[[(2S)-1-[(2S)-4-amino-4-oxo-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]butanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoic acid
Appearance
Lyophilized Powder
Purity
≥96%
Sequence
EPNPDEFFGLM-NH2
Storage
Store at -20°C
InChI
InChI=1S/C59H81N13O17S/c1-32(2)26-38(53(83)65-35(50(61)80)22-25-90-3)64-47(75)31-62-51(81)39(27-33-12-6-4-7-13-33)67-54(84)40(28-34-14-8-5-9-15-34)68-52(82)36(19-21-48(76)77)66-55(85)41(30-49(78)79)69-56(86)43-16-11-24-72(43)59(89)42(29-45(60)73)70-57(87)44-17-10-23-71(44)58(88)37-18-20-46(74)63-37/h4-9,12-15,32,35-44H,10-11,16-31H2,1-3H3,(H2,60,73)(H2,61,80)(H,62,81)(H,63,74)(H,64,75)(H,65,83)(H,66,85)(H,67,84)(H,68,82)(H,69,86)(H,70,87)(H,76,77)(H,78,79)/t35-,36-,37-,38-,39-,40-,41-,42-,43-,44-/m0/s1
InChI Key
DCZICFAYZIXKNW-BLDAPKAQSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C3CCCN3C(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C5CCC(=O)N5
1. Effect of PG-SPI and PG-KII, two novel and natural tachykinins, on salivary secretion in the rat
M Broccardo, G Improta, A Brandoni, A Tabacco Peptides. 1996;17(4):729-31. doi: 10.1016/0196-9781(96)00052-6.
In an in vivo study of salivation in rats, the scialogogic effects of two natural and amphibian tachykinins, PG-SPI and PG-KII, which activate distinct tachykinin receptors, were compared with those of the tachykinins substance P, neurokinin A and B, and kassinin. The rank order of potencies of these peptides injected intravenously on salivation was: PG-SPI = SP > or = PG-KII = KASS > NKA > > NKB. Atropine (1 mg/kg. i.v.) had no effect on PG-SPI-, SP-, and NKA-induced salivation, but reduced that stimulated by PG-KII and KASS. We conclude that PG-SPI and PG-KII increase salivary secretion through different mechanisms and that rat salivary glands contain PG-SPI-and PG-KII-sensitive receptors.
2. Parallel bioassay of PG-SPI, an amphibian acidic SP-like peptide, mammalian basic substance P, and neurokinins A and B on in vitro and in vivo test systems
M Broccardo, G Improta, C Severini Peptides. 1995;16(4):609-14. doi: 10.1016/0196-9781(95)91323-6.
In vitro and in vivo test systems were used to compare the biological activities of substance P and the neurokinins A and B with those of a newly isolated substance P-like acidic peptide, PG-SPI (pGlu-Pro-Asn-Pro-Asp-Glu-Phe-Phe-Gly-Leu-Met-NH2). On nearly all the isolated smooth muscle preparations tested, PG-SPI appeared only slightly more potent than SP, but on guinea pig trachea it was 50 times more potent. The in vitro spasmogenic effect of PG-SPI on guinea pig trachea was inhibited by the NK1 receptor antagonist, CP 96,345. In in vivo tests, intracerebroventricularly injected PG-SPI was about 20 times more potent than SP in inhibiting gastric acid secretion and emptying in rats. Tests with antagonists showed that CP 96,345 reduced PG-SPI-induced inhibition of gastric emptying and the NK2 receptor antagonist, MEN 10,376, sharply blocked PG-SPI-induced inhibition of gastric acid secretion. These findings fit poorly into the current classification of tachykinin receptors and suggest that the acidic substance P-like peptide is a valuable tool for studying the functional role of other tachykinin receptor subtypes.
3. Effects of supraspinal administration of PG-SPI and PG-KII, two amphibian tachykinin peptides, on nociception in the rat
G Improta, M Broccardo Peptides. 2000 Nov;21(11):1611-6. doi: 10.1016/s0196-9781(00)00292-8.
We investigated and compared the effects of two amphibian tachykinins, the NK1 receptor agonist PG-SPI and the NK3 receptor agonist PG-KII, and the mammalian tachykinins substance P, neurokinin A and neurokinin B on the reaction time to a painful radiant heat stimulus (tail-flick test in rats) after intracerebroventricular injection. PG-SPI (1, 10 and 20 microg) and PG-KII (1, 5 and 10 microg) significantly increased the reaction time. Substance P (10 microg) injected intracerebroventricularly induced antinociception, whereas neurokinin A and neurokinin B did not. Like analgesia evoked by exogenous substance P, PG-SPI-evoked analgesia was blocked by pretreatment with naloxone. Naloxone left PG-KII antinociception unchanged, but the NK3 receptor selective antagonist markedly reduced it. These findings suggest NK1 and NK3 tachykinin receptor system involvement in supraspinal analgesia in rats.
Online Inquiry
Verification code
Inquiry Basket